Jinyu's R&D

Intelligent manufacturing

We are the first Intelligent Manufacturing solution in veterinary vaccines. We are the first Intelligent Manufacturing solution in veterinary vaccines. The whole production process is completed under the most optimized parameters, committed to resolve the difference issue between production batches, and to ensure the product quality stable, efficient and controllable.

Three national laboratories

Chinese National Engineering Laboratory for Veterinary Vaccines

With a total investment of USD 21 million and a building area of 16,800 sqm, the lab aims to carry out diagnostic detection, cell culturing, virus isolation, constructing and expressing new vaccine strains, purification and concentration, process optimization, evaluation and registration, as well as tracking and monitoring epidemic trends for disease prevention and control.

Key Laboratory of Ruminant Biological Products of MARA of China

With a total investment of USD 6.7 million and a building area of 5,348 sqm, the lab focuses on solving the problem of disease prevention and control of cattle and sheep with the diagnosis and detection of ruminant animal diseases, isolation and identification of bacteria and viruses, and development and application of multivalent vaccines and updated iterative vaccines.

ABSL-3 Laboratory (P3)

With a total investment of USD 42 million and a building area of 12,000 sqm, as the first ABSL-3 lab with the largest scale and most complete functions built by enterprises, it is designed for the research and evaluation of pathogen isolation and identification of foreign diseases, unknown diseases, severe infectious diseases and zoonotic diseases, as well as the development of related vaccines, such as ASFV, FMDV, Brucellosis, etc.

  • Annual R&D investment: More than 10% of turnover in long-term

    Annual R&D Investment

    More Than
    10% of Turnover
    In Long-Term

  • Accumulated R&D investment in the past five years: USD 175 Million (2017 - 2023)

    Accumulated R&D Investment

    USD 175 Million
    (2017 - 2023)

  • R&D Team Members: 362 (up to 2023)

    R&D Team Members

    362
    (up to 2023)